Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Following the results of the EMPA-REG OUTCOME trial with Empagliflozin, is it possible to speak of a class effect?

Vista senzilla d'ítem
dc.contributor.authorAmpudia-Blasco, Francisco Javier
dc.contributor.authorRomera, Irene
dc.contributor.authorAriño, Bernat
dc.contributor.authorGomis, Ramon, 1946-
dc.date.accessioned2017-03-17T14:48:07Z
dc.date.available2017-03-17T14:48:07Z
dc.date.issued2017-01-13
dc.date.updated2017-03-17T14:48:07Z
dc.description.abstractThe recently published cardiovascular outcomes data for the first sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, have shown cardiovascular safety and additional benefits in patients with type 2 diabetes and established cardiovascular disease. Empagliflozin showed lower rates of death from cardiovascular causes or from any causes and lower hospitalization rates from heart failure compared with placebo, both in addition to standard care. This commentary discusses the existence of a possible class effect considering the available evidence described for other SGLT2 inhibitors.
dc.format.extent4 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec669654
dc.identifier.issn1178-7074
dc.identifier.pmid28144158
dc.identifier.urihttps://hdl.handle.net/2445/108575
dc.language.isoeng
dc.relation.isformatofhttps://doi.org/10.2147/IJGM.S115566
dc.relation.ispartofInternational Journal of General Medicine, 2017, vol. 10, p. 23-26
dc.relation.urihttps://doi.org/10.2147/IJGM.S115566
dc.rightscc-by-nc (c) Ampudia-Blasco, Francisco Javier, 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationMalalties cardiovasculars
dc.subject.classificationDiabetis
dc.subject.classificationGlucosa
dc.subject.otherCardiovascular diseases
dc.subject.otherDiabetes
dc.subject.otherGlucose
dc.titleFollowing the results of the EMPA-REG OUTCOME trial with Empagliflozin, is it possible to speak of a class effect?
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
669654.pdf
Mida:
112.02 KB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Medicina)